Products - Multiple sclerosis | Topic | NICE

Showing 17 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter
Status: PublishedRemove ‘Status: Published’ filter

Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
21 May 2024
Published:
28 May 2014
Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 June 2018
Cladribine for treating active relapsing forms of multiple sclerosis (TA1053)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 April 2025
Cladribine for treating relapsing–remitting multiple sclerosis (TA616)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
21 May 2024
Published:
19 December 2019
Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 August 2014
Diroximel fumarate for treating relapsing–remitting multiple sclerosis (TA794)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 June 2022
Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis (TA254)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 April 2012
Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis (TA127)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
21 May 2024
Published:
22 August 2007
Ocrelizumab for treating primary progressive multiple sclerosis (TA585)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 June 2019
Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 July 2018
Ofatumumab for treating relapsing multiple sclerosis (TA699)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 May 2021
Ozanimod for treating relapsing–remitting multiple sclerosis (TA706)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 June 2021
Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 February 2020
Ponesimod for treating relapsing–remitting multiple sclerosis (TA767)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 February 2022
Siponimod for treating secondary progressive multiple sclerosis (TA656)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 November 2020
Teriflunomide for treating relapsing–remitting multiple sclerosis (TA303)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
1 June 2014
Published:
22 January 2014
Ublituximab for treating relapsing multiple sclerosis (TA1025)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 December 2024